Michael R. Darby
Research Subjects
Research Interests
Michael R. Darby has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Lynne G. Zucker
7 shared publications- Lynne G. Zucker
University of California, Los Angeles, Los Angeles, CA 90095, USA
5 shared publications - Andrew Wang
Wang: Senior Economist, Office of Economic Assessment, Advanced Technology Program, National Institute of Standards and Technology, Gaithersburg, MD 20899. Phone 1‐301‐975‐5374, Fax 1‐301‐975‐4776, E‐mail
1 shared publication Angelo R. Mascaro
1 shared publicationArnold C. Harberger
1 shared publicationDavid E. Lindsey
1 shared publication
Latest Publications
- 15 May 2012
- Published by SAGE Publications
- p. 17-34
Costly Information: Firm Transformation, Exit, or Persistent Failure
- 15 May 2012
- Published by SAGE Publications
- p. 17-34
Costly Information: Firm Transformation, Exit, or Persistent Failure
- 29 May 2009
- Published by Edward Elgar Publishing
Star Scientists, Innovation and Regional and National Immigration
- 29 May 2009
- Published by Edward Elgar Publishing
Star Scientists, Innovation and Regional and National Immigration
- Open Access
- 23 August 2007
- Published by Elsevier in Papers in Regional Science
- Vol. 86 (3) , 445-471
Virtuous circles in science and commerce
- 23 August 2007
- Published by Elsevier in Papers in Regional Science
- Vol. 86 (3) , 445-471
Open AccessVirtuous circles in science and commerce
- 1 July 2007
- Published by Elsevier in Research Policy
- Vol. 36 (6) , 850-863
Minerva unbound: Knowledge stocks, knowledge flows and new knowledge production
- 1 July 2007
- Published by Elsevier in Research Policy
- Vol. 36 (6) , 850-863
Minerva unbound: Knowledge stocks, knowledge flows and new knowledge production
- 1 July 2004
- Published by Wiley in Economic Inquiry
- Vol. 42 (3) , 351-369
High Stakes in High Technology: High‐Tech Market Values as Options
In science‐based industries, world‐class scientists drive the most successful firms. These scientists are more likely to follow high‐stakes, high‐returns R&D strategies instead of more predictable incremental strategies. We develop an options pricing model in which the probability of stock‐price jumps increases with knowledge capital. GMM estimates show the probability of stock‐price jumps increases with three measures of knowledge capital intensity, two of which can be reasonably estimated contemporaneously. The model explains most variation in biotech firm market values. Firms with two standard deviations more knowledge capital are valued 10–50% more than firms with mean values of all variables.
- 1 July 2004
- Published by Wiley in Economic Inquiry
- Vol. 42 (3) , 351-369
High Stakes in High Technology: High‐Tech Market Values as Options
In science‐based industries, world‐class scientists drive the most successful firms. These scientists are more likely to follow high‐stakes, high‐returns R&D strategies instead of more predictable incremental strategies. We develop an options pricing model in which the probability of stock‐price jumps increases with knowledge capital. GMM estimates show the probability of stock‐price jumps increases with three measures of knowledge capital intensity, two of which can be reasonably estimated contemporaneously. The model explains most variation in biotech firm market values. Firms with two standard deviations more knowledge capital are valued 10–50% more than firms with mean values of all variables.
- 1 April 2004
- Published by Wiley in Contemporary Economic Policy
- Vol. 22 (2) , 145-161
Joint Ventures, Universities, and Success in the Advanced Technology Program
- 1 April 2004
- Published by Wiley in Contemporary Economic Policy
- Vol. 22 (2) , 145-161
Joint Ventures, Universities, and Success in the Advanced Technology Program
- 1 January 2003
- Published by Wiley in Economic Inquiry
- Vol. 41 (1) , 1-19
Growing by Leaps and Inches: Creative Destruction, Real Cost Reduction, and Inching Up
Most firms achieve perfective progress, incrementally improving commodities or productivity. But technological progress is concentrated in a few firms achieving metamorphic progress: forming or transforming industries with technological breakthroughs (e.g., biotechnology, lasers, semiconductors, nanotechnology). Unless congruent with incumbents' science and technology base, metamorphic progress promotes entry. Scientific breakthroughs embodied in discovering scientists, protected by natural excludability and transferred by learning‐by‐doing‐with at the bench generally drive metamorphic progress. Embodied knowledge is rivalrous and leads to entry and industry dominance by star scientist–linked firms. Incorporating this scientific entrepreneurial process is essential to improving—if not transforming—endogenous growth models.
- 1 January 2003
- Published by Wiley in Economic Inquiry
- Vol. 41 (1) , 1-19
Growing by Leaps and Inches: Creative Destruction, Real Cost Reduction, and Inching Up
Most firms achieve perfective progress, incrementally improving commodities or productivity. But technological progress is concentrated in a few firms achieving metamorphic progress: forming or transforming industries with technological breakthroughs (e.g., biotechnology, lasers, semiconductors, nanotechnology). Unless congruent with incumbents' science and technology base, metamorphic progress promotes entry. Scientific breakthroughs embodied in discovering scientists, protected by natural excludability and transferred by learning‐by‐doing‐with at the bench generally drive metamorphic progress. Embodied knowledge is rivalrous and leads to entry and industry dominance by star scientist–linked firms. Incorporating this scientific entrepreneurial process is essential to improving—if not transforming—endogenous growth models.
- 1 July 2002
- Published by University of Chicago Press in Journal of Labor Economics
- Vol. 20 (3) , 629-660
Labor Mobility from Academe to Commerce
Journal articleIFPRI3; ISIMTIDP
- 1 July 2002
- Published by University of Chicago Press in Journal of Labor Economics
- Vol. 20 (3) , 629-660
Labor Mobility from Academe to Commerce
Journal articleIFPRI3; ISIMTIDP
- Top Cited Papers
- 1 January 2002
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
- Vol. 48 (1) , 138-153
Commercializing Knowledge: University Science, Knowledge Capture, and Firm Performance in Biotechnology
Commercializing knowledge involves transfer from discovering scientists to those who will develop it commercially. New codes and formulae describing discoveries develop slowly-with little incentive if value is low and many competing opportunities if high. Hence new knowledge remains naturally excludable and appropriable. Team production allows more knowledge capture of tacit, complex discoveries by firm scientists. A robust indicator of a firm's tacit knowledge capture (and strong predictor of its success) is the number of research articles written jointly by firm scientists and discovering, “star” scientists, nearly all working at top universities. An operationally attractive generalization of our star measure-collaborative research articles between firm scientists and top research university scientists-replicates the impact on firm success. In panel analyses, publications by firm scientists with stars and/or top 112 university scientists increase the number and citation rate for firm patents. Further, star articles increase these rates significantly more than other top 112 university scientists' articles. Cross-sectional analyses of products and employment show a similar pattern of positive effects on firms' success of collaborations with stars or top university scientists, but estimates of differential effects are nonrobust due to multicollinearity. Venture capital funding has significant, usually positive effects on firm success.
- 1 January 2002
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
- Vol. 48 (1) , 138-153
Top Cited PapersCommercializing Knowledge: University Science, Knowledge Capture, and Firm Performance in Biotechnology
Commercializing knowledge involves transfer from discovering scientists to those who will develop it commercially. New codes and formulae describing discoveries develop slowly-with little incentive if value is low and many competing opportunities if high. Hence new knowledge remains naturally excludable and appropriable. Team production allows more knowledge capture of tacit, complex discoveries by firm scientists. A robust indicator of a firm's tacit knowledge capture (and strong predictor of its success) is the number of research articles written jointly by firm scientists and discovering, “star” scientists, nearly all working at top universities. An operationally attractive generalization of our star measure-collaborative research articles between firm scientists and top research university scientists-replicates the impact on firm success. In panel analyses, publications by firm scientists with stars and/or top 112 university scientists increase the number and citation rate for firm patents. Further, star articles increase these rates significantly more than other top 112 university scientists' articles. Cross-sectional analyses of products and employment show a similar pattern of positive effects on firms' success of collaborations with stars or top university scientists, but estimates of differential effects are nonrobust due to multicollinearity. Venture capital funding has significant, usually positive effects on firm success.
- 1 January 1999
- Published by Inderscience Publishers in International Journal of Biotechnology
- Vol. 1 (1) , 119
Star-scientist linkages to firms in APEC and European countries: indicators of regional institutional differences affecting competitive advantage
Based on publications and affiliations of the world's best ''star'' bioscientists, who have been shown elsewhere to be crucial not only in the advance of the science but also in its commercialisation, APEC countries (particularly the USA and Japan) have done substantially better than Europe in producing these scientists, in attracting them from other countries while retaining their own, and in fostering bench-science level collaborations of star scientists with scientists in their country's new biotechnology enterprises. Such differences in scientific performance and commercialisation are ultimately due to underlying differences in policies, institutions, and cultures. Where standalone institutes, not part of universities or firms, are more prevalent, star-firm collaborations are significantly reduced. Restrictive rules on university faculty participation in commercial activities are also identified as a significant factor for further research. The factors that impede scientific advance and commercialisation in biotechnology may be even more important as indicators of future competitive advantage in other emerging science-driven high-technology industries.
- 1 January 1999
- Published by Inderscience Publishers in International Journal of Biotechnology
- Vol. 1 (1) , 119
Star-scientist linkages to firms in APEC and European countries: indicators of regional institutional differences affecting competitive advantage
Based on publications and affiliations of the world's best ''star'' bioscientists, who have been shown elsewhere to be crucial not only in the advance of the science but also in its commercialisation, APEC countries (particularly the USA and Japan) have done substantially better than Europe in producing these scientists, in attracting them from other countries while retaining their own, and in fostering bench-science level collaborations of star scientists with scientists in their country's new biotechnology enterprises. Such differences in scientific performance and commercialisation are ultimately due to underlying differences in policies, institutions, and cultures. Where standalone institutes, not part of universities or firms, are more prevalent, star-firm collaborations are significantly reduced. Restrictive rules on university faculty participation in commercial activities are also identified as a significant factor for further research. The factors that impede scientific advance and commercialisation in biotechnology may be even more important as indicators of future competitive advantage in other emerging science-driven high-technology industries.